Treatment of Multidrug-Resistant Tuberculosis in Children and Adolescents

Chiang, Silvia S.; Furin, Jennifer

doi:10.1055/s-0037-1607234

Cited by 2 publications

(1 citation statement)

References 73 publications

(97 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nine (45%) children were orphans, and 14 (70%) came from households where alcohol abuse was present-unsurprising findings given the high rates of death and alcohol abuse among adults with MDR-TB in Ukraine [11]. Hospitalization of children for MDR-TB treatment usually is not medically indicated [23]; however, it is possible that hospitalization prevents loss to follow-up in children with social risk factors. Nevertheless, hospitalization during TB treatment-a practice that persists in Ukraine and other former Soviet republics-can cause social and psychological problems in children.…”

Section: Discussionmentioning

confidence: 99%

Pediatric Multidrug-resistant Tuberculosis in Kyiv City, Ukraine

Chiang

Sheremeta

Padilla

et al. 2019

JEGH

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Pediatric Multidrug-resistant Tuberculosis in Kyiv City, Ukraine

Chiang

Sheremeta

Padilla

et al. 2019

JEGH

View full text Add to dashboard Cite

Treatment Outcomes Among Pediatric Patients With Highly Drug-Resistant Tuberculosis: The Role of New and Repurposed Second-Line Tuberculosis Drugs

Madzgharashvili

Salindri

Magee

et al. 2020

Journal of the Pediatric Infectious Diseases Society

View full text Add to dashboard Cite

Background Among pediatric patients with multidrug-resistant tuberculosis (MDR-TB), limited data exist regarding treatment outcomes in the context of the new and repurposed second-line TB drugs (SLDs). We aimed to describe the treatment outcomes among pediatric MDR-TB patients receiving new and repurposed SLDs including the proportion who achieved favorable outcomes. Methods We conducted a retrospective cohort study among pediatric patients (age ≤18 years) treated for MDR-TB in the country of Georgia from 2009 to 2016. A “new and repurposed” SLD regimen was defined as a regimen that included linezolid, bedaquiline, and/or delamanid. Favorable treatment outcome was defined by treatment completion or documented microbial “cure” status at the end of treatment. We assessed the association between the use of the new and repurposed SLDs with MDR-TB treatment outcomes using bivariate analyses and log-binomial regression. Results There were 124 pediatric MDR-TB patients (median age: 13.7; interquartile range: 4.6-16.0) initiating treatment; 119 (96.0%) had a treatment outcome recorded and were included in our analyses. Eighteen (15.1%) patients received new and repurposed SLDs from 2015 or later. After adjusting for potential confounders, the proportion achieving favorable MDR-TB treatment outcomes was higher among patients treated with SLD regimens that included new and/or repurposed drugs when compared with those treated without (adjusted risk ratio: 1.17; 95% confidence interval: 0.51-2.72). Conclusions We observed a high proportion of favorable treatment outcomes among pediatric patients with MDR-TB receiving the new and repurposed SLDs. Further studies to evaluate the efficacy and children’s tolerability of the new and repurposed SLDs are still warranted.

show abstract

Treatment of Multidrug-Resistant Tuberculosis in Children and Adolescents

Cited by 2 publications

References 73 publications

Pediatric Multidrug-resistant Tuberculosis in Kyiv City, Ukraine

Pediatric Multidrug-resistant Tuberculosis in Kyiv City, Ukraine

Treatment Outcomes Among Pediatric Patients With Highly Drug-Resistant Tuberculosis: The Role of New and Repurposed Second-Line Tuberculosis Drugs

Contact Info

Product

Resources

About